Conformational Flexibility in the Immunoglobulin-Like Domain of the Hepatitis C Virus Glycoprotein E2
Open Access
- 5 July 2017
- journal article
- research article
- Published by American Society for Microbiology in mBio
- Vol. 8 (3) , e00382-17
Abstract
The hepatitis C virus (HCV) glycoprotein E2 is the major target of neutralizing antibodies and is therefore highly relevant for vaccine design. Its structure features a central immunoglobulin (Ig)-like β-sandwich that contributes to the binding site for the cellular receptor CD81. We show that a synthetic peptide corresponding to a β-strand of this Ig-like domain forms an α-helix in complex with the anti-E2 antibody DAO5, demonstrating an inside-out flip of hydrophobic residues and a secondary structure change in the composite CD81 binding site. A detailed interaction analysis of DAO5 and cross-competing neutralizing antibodies with soluble E2 revealed that the Ig-like domain is trapped by different antibodies in at least two distinct conformations. DAO5 specifically captures retrovirus particles bearing HCV glycoproteins (HCVpp) and infectious cell culture-derived HCV particles (HCVcc). Infection of cells by DAO5-captured HCVpp can be blocked by a cross-competing neutralizing antibody, indicating that a single virus particle simultaneously displays E2 molecules in more than one conformation on its surface. Such conformational plasticity of the HCV E2 receptor binding site has important implications for immunogen design. IMPORTANCE Recent advances in the treatment of hepatitis C virus (HCV) infection with direct-acting antiviral drugs have enabled the control of this major human pathogen. However, due to their high costs and limited accessibility in combination with the lack of awareness of the mostly asymptomatic infection, there is an unchanged urgent need for an effective vaccine. The viral glycoprotein E2 contains regions that are crucial for virus entry into the host cell, and antibodies that bind to these regions can neutralize infection. One of the major targets of neutralizing antibodies is the central immunoglobulin (Ig)-like domain within E2. We show here that this Ig-like domain is conformationally flexible at the surface of infectious HCV particles and pseudoparticles. Our study provides novel insights into the interactions of HCV E2 with the humoral immune system that should aid future vaccine development.Keywords
Funding Information
- Deutsche Forschungsgemeinschaft (Project B10 of the Collaborative Research Centre SFB900)
- Deutsche Forschungsgemeinschaft (Project A6 of the Collaborative Research Centre SFB900)
- Institut Pasteur
- Agence Nationale de Recherches sur le Sida et les Hépatites Virales
- Agence Nationale de Recherches sur le Sida et les Hépatites Virales
- RCUK | Medical Research Council (MC_UU12014/2)
This publication has 52 references indexed in Scilit:
- Structural flexibility at a major conserved antibody target on hepatitis C virus E2 antigenProceedings of the National Academy of Sciences, 2016
- Antibody Response to Hypervariable Region 1 Interferes with Broadly Neutralizing Antibodies to Hepatitis C VirusJournal of Virology, 2016
- Structural Flexibility of a Conserved Antigenic Region in Hepatitis C Virus Glycoprotein E2 Recognized by Broadly Neutralizing AntibodiesJournal of Virology, 2015
- Discrete conformations of epitope II on the hepatitis C virus E2 protein for antibody-mediated neutralization and nonneutralizationProceedings of the National Academy of Sciences, 2014
- Production of Recombinant Antibodies in Drosophila melanogaster S2 Cells2012
- Neutralizing Monoclonal Antibodies against Hepatitis C Virus E2 Protein Bind Discontinuous Epitopes and Inhibit Infection at a Postattachment StepJournal of Virology, 2011
- Characterization of the Envelope Glycoproteins Associated with Infectious Hepatitis C VirusJournal of Virology, 2010
- A Point Mutation Leading to Hepatitis C Virus Escape from Neutralization by a Monoclonal Antibody to a Conserved Conformational EpitopeJournal of Virology, 2008
- Study of a novel hypervariable region in hepatitis C virus (HCV) E2 envelope glycoproteinVirology, 2006
- Human Monoclonal Antibodies That Inhibit Binding of Hepatitis C Virus E2 Protein to CD81 and Recognize Conserved Conformational EpitopesJournal of Virology, 2000